Patents by Inventor James Davenport
James Davenport has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11905270Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseaseas a sole agent or in combination with other active ingredients.Type: GrantFiled: December 18, 2017Date of Patent: February 20, 2024Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Stefan Baeurle, Adam James Davenport, Christopher Stimson, Jens Nagel, Nicole Schmidt, Andrea Rotgeri, Ina Groeticke, Alexandra Rausch, Juergen Klar, Thomas Dyrks
-
Publication number: 20230271953Abstract: The present invention relates to compounds that act as DUX4 repressors, suitable for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.Type: ApplicationFiled: November 27, 2020Publication date: August 31, 2023Applicant: Facio Intellectual Property B.V.Inventors: Pui Leng Loke, Joris Herman De Maeyer, Robert David Matthew Pace, Simon Fletcher Elwood, Gregory Foulkes, Andrew Anighoro, Ainoa Rueda-Zubiaurre, Jonathan Philip Richards, Adam James Davenport, Cristina Lecci, Anthony Paul Dickie, Gerd Schnorrenberg
-
Publication number: 20230086179Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 18, 2017Publication date: March 23, 2023Inventors: Stefan BAEURLE, Adam James DAVENPORT, Christopher STIMSON, Jens NAGEL, Nicole SCHMIDT, Andrea ROTGERI, Ina GROETICKE, Alexandra RAUSCH, Juergen KLAR, Thomas DYRKS
-
Publication number: 20230053411Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: September 9, 2021Publication date: February 23, 2023Applicant: Bayer AktiengesellschaftInventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
-
Publication number: 20230052017Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.Type: ApplicationFiled: November 27, 2020Publication date: February 16, 2023Applicant: Facio Intellectual Property B.V.Inventors: Pui Leng Loke, Joris Herman De Maeyer, Robert David Matthew Pace, Gregory Foulkes, Ainoa Rueda-Zubiaurre, Simon Fletcher Ellwood, Adam James Davenport, Anthony Paul Dickie, Gerd Schnorrenberg
-
Publication number: 20230043209Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: September 17, 2021Publication date: February 9, 2023Inventors: Stefan BAEURLE, Adam James DAVENPORT, Christopher STIMSON, Jens NAGEL, Nicole SCHMIDT, Andrea ROTGERI, Ina GROETICKE, Alexandra RAUSCH, Juergen KLAR, Thomas DYRKS
-
Patent number: 11319324Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 18, 2018Date of Patent: May 3, 2022Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Marcus Koppitz, Holger Siebeneicher, Nico Bräuer, Elisabeth Pook, Andrea Rotgeri, Roland Neuhaus, Oliver Martin Fischer, Jens Nagel, Adam James Davenport, James Lindsay Carr, Robert James Townsend, Nina Connelly Ursinyova, Shelley Anne Parrott
-
Patent number: 11165162Abstract: The present disclosure relates to a dichroic spherical antenna. In one embodiment of the present disclosure, a dichroic spherical antenna comprises a collector disposed within a spherically-shaped reflector; wherein the reflector comprises a coating. In some embodiments, the coating comprises a plurality of ferromagnetic particles dispersed throughout an epoxy-based medium. In some embodiments, the collector's interior is held at a pressure less than the pressure exerted on the exterior of the collector. The present disclosure also relates to a method of receiving radio signals, the method comprising the steps of receiving, at a collector disposed inside a spherical reflector, electromagnetic radiation; wherein the exterior of the reflector comprises a coating.Type: GrantFiled: April 22, 2019Date of Patent: November 2, 2021Assignee: New Mexico Aerospace LLCInventor: Benjamin James Davenport
-
Publication number: 20210317128Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 18, 2018Publication date: October 14, 2021Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Nico BRÄUER, Elisabeth POOK, Andrea ROTGERI, Roland NEUHAUS, Oliver Martin FISCHER, Jens NAGEL, Adam James DAVENPORT, James Lindsay CARR, Robert James TOWNSEND, Nina CONNELLY URSINYOVA, Shelley Anne PARROTT
-
Publication number: 20210317092Abstract: The present invention relates to tetrazole containing compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease syndrome, condition, or symptoms, in particular related to chronic pain and inflammation, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 18, 2017Publication date: October 14, 2021Inventors: Stefan BÄEURLE, Adam James DAVENPORT, Christopher STIMSON, James Lindsay CARR, Christian Abingdon BUBERT, Frédéric Jacques MARLIN, Jens NAGEL, Nicole SCHMIDT, Andrea ROTGERI, Horst IRLBACHER
-
Patent number: 11142523Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 1, 2019Date of Patent: October 12, 2021Assignee: Bayer AktiengesellschaftInventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
-
Publication number: 20210059471Abstract: A portable outdoor grill and method for cooking in windy outdoor environments protects food on a grill grate from wind-blown debris by retaining the grill grate at an offset position away from a rim that forms at an open grill end of the portable outdoor grill. The food is circumferentially surrounded by the sidewalls at the grill end of the portable outdoor grill. The heat fuel is circumferentially surrounded by the sidewalls at the base end of the grill. Multiple fastening apertures and grate support fasteners enable height adjustability of the grill grate along the length of the housing. Multiple vent apertures form in the sidewalls to enable air circulation for enhanced grilling. Insulated handles facilitate gripping and manipulation of the portable outdoor grill. A Z-shaped spatula facilitates access to the offset grill grate below the rim.Type: ApplicationFiled: August 29, 2019Publication date: March 4, 2021Inventor: James Davenport Hundley, JR.
-
Publication number: 20200131169Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 1, 2019Publication date: April 30, 2020Applicant: Bayer AktiengesellschaftInventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
-
Patent number: 10519105Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).Type: GrantFiled: April 21, 2017Date of Patent: December 31, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Kentaro Yashiro, Masashi Kato, Tetsuji Saito, Takuya Okada, Daisuke Wakamatsu, Adam James Davenport, Christopher Charles Stimson
-
Patent number: 10472354Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: November 15, 2018Date of Patent: November 12, 2019Assignee: Bayer AktiengesellschaftInventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
-
Publication number: 20190194148Abstract: The present invention relates to N-(tetrazolylaryl) amide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 6, 2018Publication date: June 27, 2019Inventors: Stefan Bäurle, Jens Nagel, Andrea Rotgeri, Adam James Davenport, Christopher Charles Stimson
-
Publication number: 20190185466Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 15, 2018Publication date: June 20, 2019Applicant: Bayer AktiengesellschaftInventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO, Jürgen KLAR
-
Publication number: 20190177284Abstract: The present invention relates to tetrazolyl-containing cyclopropanecarboxamides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 6, 2018Publication date: June 13, 2019Inventors: Stefan Bäurle, Jens Nagel, Andrea Rotgeri, Adam James Davenport, Christopher Charles Stimson
-
Publication number: 20190177279Abstract: The present invention relates to carboxylic acid aromatic 1,2-cyclopropylamides of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 6, 2018Publication date: June 13, 2019Inventors: Stefan Bäurle, Jens Nagel, Andrea Rotgeri, Adam James Davenport, Christopher Charles Stimson
-
Publication number: 20190127320Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (1) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (1) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).Type: ApplicationFiled: April 21, 2017Publication date: May 2, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Kentaro YASHIRO, Masashi KATO, Tetsuji SAITO, Takuya OKADA, Daisuke WAKAMATSU, Adam James DAVENPORT, Christopher Charles STIMSON